The three patients with age-related tau-pathology had a documented median disease duration of 1.25 years (range 0.5–2 years) while those patients with classical anti-IgLON5-related tauopathy or PSP with prominent brainstem involvement had a median disease duration of 9 years (range 0.5–13 years) (p = 0.11). The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.